Background: Several reports suggest testosterone replacement therapy (TRT) may be an option in selected hypogonadal patients with a history of prostate cancer (PCa) and no evidence of disease after curative treatment. Our aim was to assess TRT experience and patient management among urologists in Bavaria. Materials and Methods: Questionnaires were developed and mailed to all registered urologists in Bavaria (n = 420) regarding their experience with TRT in patients with treated PCa. Results: One hundred and ninety-three (46%) urologists returned the questionnaire and reported their experience with TRT in hypogonadal patients after curative treatment for PCa. Complete data was available for 32 men. Twenty-six patients (81%) received TRT after prostatectomy, 1 patient after external beam radiation, 3 patients after high-dose brachytherapy and 2 patients after high-intensity focused ultrasound. Of the PCa cases, 88.5% (23/26) were organ confined (pT2a-c), and 3 were pT3 tumors. All patients were pN0/cN0, and only 1 patient (pT3a) had a positive surgical margin status postoperatively. After a mean follow-up of 39.8 months, no biochemical relapse was observed. Conclusion: To date, there is no clear evidence to withhold TRT from hypogonadal men after curative PCa treatment. Our findings, although with limitations, fit in with the available data showing that TRT does not put patients at an increased risk after curative treatment of PCa.

Keywords:
Testosterone replacement therapy, Prostate cancer, Hypogonadal men
1.
Zitzmann M, Faber S, Nieschlag E: Association of specific symptoms and metabolic risks with serum testosterone in older men. J Clin Endocrinol Metab 2006;91:4335-4343.
2.
Huggins C, Hodges CV: Studies on prostatic cancer. I. The effect of castration, of estrogen, and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1941;1:293-297.
3.
Morgentaler A: Testosterone replacement therapy and prostate cancer. Urol Clin North Am 2007;34:555-563.
4.
Morgentaler A: Testosterone therapy in men with prostate cancer: scientific and ethical considerations. J Urol 2013;189:S26-S33.
5.
Morgentaler A, Rhoden EL: Prevalence of prostate cancer among hypogonadal men with prostate-specific antigen levels of 4.0 ng/ml or less. Urology 2006;68:1263-1267.
6.
Hoffman MA, DeWolf WC, Morgentaler A: Is low serum free testosterone a marker for high grade prostate cancer? J Urol 2000;163:824-827.
7.
Ribeiro M, Ruff P, Falkson G: Low serum testosterone and a younger age predict for a poor outcome in metastatic prostate cancer. Am J Clin Oncol 1997;20:605-608.
8.
Turo R, Tan K, Thygesen H, Sundaram SK, Chahal R, Prescott S, Cross WR: Diethylstilboestrol (1 mg) in the management of castration-resistant prostate cancer. Urol Int 2014, Epub ahead of print.
9.
Porcaro AB, Petrozziello A, Ghimenton C, Migliorini F, Sava T, Caruso B, Romano M, Cavalleri S, Artibani W: Associations of pretreatment serum total testosterone measurements with pathology-detected Gleason score cancer. Urol Int 2014;93:269-278.
10.
Fowler JE Jr, Whitmore WF Jr: The response of metastatic adenocarcinoma of the prostate to exogenous testosterone. J Urol 1981;126:372-375.
11.
Endogenous Hormones and Prostate Cancer Collaborative Group: Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies. J Natl Cancer Inst 2008;100:170-183.
12.
Marks LS, Mazer NA, Mostaghel E, Hess DL, Dorey FJ, Epstein JI, Veltri RW, Makarov DV, Partin AW, Bostwick DG, Macairan ML, Nelson PS: Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trial. JAMA 2006;296:2351-2361.
13.
Labrie F: Blockade of testicular and adrenal androgens in prostate cancer treatment. Nat Rev Urol 2011;8:73-85.
14.
Goldenberg SL, Koupparis A, Robinson ME: Differing levels of testosterone and the prostate: a physiological interplay. Nat Rev Urol 2011;8:365-377.
15.
Tindall DJ, Rittmaster RS: The rationale for inhibiting 5alpha-reductase isoenzymes in the prevention and treatment of prostate cancer. J Urol 2008;179:1235-1242.
16.
Page ST, Lin DW, Mostaghel EA, Hess DL, True LD, Amory JK, Nelson PS, Matsumoto AM, Bremner WJ: Persistent intraprostatic androgen concentrations after medical castration in healthy men. J Clin Endocrinol Metab 2006;91:3850-3856.
17.
Thigpen AE, Silver RI, Guileyardo JM, Casey ML, McConnell JD, Russell DW: Tissue distribution and ontogeny of steroid 5alpha-reductase isozyme expression. J Clin Invest 1993;92:903-910.
18.
Silver RI, Wiley EL, Davis DL, Thigpen AE, Russell DW, McConnell JD: Expression and regulation of steroid 5alpha-reductase 2 in prostate disease. J Urol 1994;152:433-437.
19.
Bartsch W, Klein H, Schiemann U, Bauer HW, Voigt KD: Enzymes of androgen formation and degradation in the human prostate. Ann NY Acad Sci 1990;595:53-66.
20.
Labrie F, Luu-The V, Labrie C, Simard J: DHEA and its transformation into androgens and estrogens in peripheral target tissues: intracrinology. Front Neuroendocrinol 2001;22:185-212.
21.
Morote J, Orsola A, Planas J, Trilla E, Raventós CX, Cecchini L, Catalán R: Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy. J Urol 2007;178:1290-1295.
22.
Chang K-H, Li-R, Papari-Zareei M, Watumull L, Zhao YD, Auchus RJ, Sharifia N: Dihydrotestosterone synthesis bypasses testosterone to drive castration-resistant prostate cancer. Proc Natl Acad Sci U S A 2011;108:13728-13733.
23.
Kaufman JM, Graydon RJ: Androgen replacement after curative radical prostatectomy for prostate cancer in hypogonadal men. J Urol 2004;172:920-922.
24.
Agarwal PK, Oefelein MG: Testosterone replacement therapy after primary treatment for prostate cancer. J Urol 2005;173:533-536.
25.
Khera M, Colen J, Grober ED, Najari BB, Murthy L, Lamb DJ, Lipshultz LI: The safety and efficacy of testosterone replacement therapy following radical prostatectomy (abstract 1164). J Urol 2007;177(suppl):384.
26.
Nabulsi O, Tal R, Gotto G, Narus J, Goldenberg L, Mulhall JP: Outcomes analysis of testosterone supplementation in hypogonadal men following radical prostatectomy (abstract 1244). J Urol 2008;179(suppl):426.
27.
Khera M, Grober ED, Najari B, Colen JS, Mohamed O, Lamb DJ, Lipshultz LI: Testosterone replacement therapy following radical prostatectomy. J Sex Med 2009;6:1165-1170.
28.
Sarosdy MF: Testosterone replacement for hypogonadism after treatment of early prostate cancer with brachytherapy. Cancer 2007;109:536-541.
29.
Daville HH, Arison CN, Hall MK, Salup R, Lockhart JL, Carrion RE: Analysis of the PSA response after testosterone supplementation in patients who have previously received management for their localized prostate cancer (abstract 1247). J Urol 2008;179(suppl):428.
30.
Morales A, Black AM, Emerson LE: Testosterone administration to men with testosterone deficiency syndrome after external beam radiotherapy for localized prostate cancer: preliminary observations. BJU Int 2009;103:62-64.
31.
Leibowitz RL, Dorff TB, Tucker S, Symanowski J, Vogelzang NJ: Testosterone replacement in prostate cancer survivors with hypogonadal symptoms. BJU Int 2010;105:1397-1401.
32.
Morgentaler A, Lipshultz LI, Bennett R, Sweeney M, Avila D Jr, Khera M: Testosterone therapy in men with untreated prostate cancer. J Urol 2011;185:1256-1261.
33.
Morales A: Effect of testosterone administration to men with prostate cancer is unpredictable: a word of caution and suggestions for a registry. BJU Int 2011;107:1369-1373.
34.
Dohle GR, Arver S, Bettocchi C, Kliesch S, Punab M, de Ronde W: Male hypogonadism. Guidelines on male Hypogonadism. EAU guidelines. http://www.uroweb.org/guidelines/online-guidelines.
35.
Yamamoto S, Kato M, Tomiyama Y, Amiya Y, Sasaki M, Shima T, Suzuki N, Murakami S, Nakatsu H, Shimazaki J: Management of men with a suspicion of prostate cancer after negative initial prostate biopsy results. Urol Int 2014;92:258-263.
36.
Isbarn H, Fisch M, Huland H, Graefen M, Sommer F: Testosterone treatment after radical prostatectomy for pathologic organ-confined prostate cancer: results from a multi-institutional study. J Urol 2010;183:e576-e577.
37.
Pastuszak AW, Pearlman AM, Godoy G, Miles BJ, Lipshultz LI, Khera M: Testosterone replacement therapy in the setting of prostate cancer treated with radiation. Int J Impot Res 2013;25:24-28.
© 2015 S. Karger AG, Basel
2015
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.